ATE215822T1 - Verwendung von rapamycin zur behandlung von anämie - Google Patents

Verwendung von rapamycin zur behandlung von anämie

Info

Publication number: ATE215822T1
Authority: AT; Austria
Prior art keywords: rapamycin; treat anemia; mammal; anemia; intrabronchially
Prior art date: 1994-12-13

Application number

AT95308503T

Other languages

English (en)

Inventor

Jay Joseph Armstrong

Original Assignee

American Home Prod

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-13

Filing date

1995-11-27

Publication date

2002-04-15

1995-11-27 Application filed by American Home Prod filed Critical American Home Prod

2002-04-15 Application granted granted Critical

2002-04-15 Publication of ATE215822T1 publication Critical patent/ATE215822T1/de

Links

208000007502 anemia Diseases 0.000 title abstract 2
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
229960002930 sirolimus Drugs 0.000 title abstract 2
241000124008 Mammalia Species 0.000 abstract 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT95308503T 1994-12-13 1995-11-27 Verwendung von rapamycin zur behandlung von anämie ATE215822T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/354,977 US5561138A (en)	1994-12-13	1994-12-13	Method of treating anemia

Publications (1)

Publication Number	Publication Date
ATE215822T1 true ATE215822T1 (de)	2002-04-15

Family

ID=23395715

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95308503T ATE215822T1 (de)	1994-12-13	1995-11-27	Verwendung von rapamycin zur behandlung von anämie

Country Status (11)

Country	Link
US (1)	US5561138A (de)
EP (1)	EP0716857B1 (de)
JP (1)	JPH08208661A (de)
KR (1)	KR100423825B1 (de)
AT (1)	ATE215822T1 (de)
CA (1)	CA2164921A1 (de)
DE (1)	DE69526311T2 (de)
DK (1)	DK0716857T3 (de)
ES (1)	ES2179862T3 (de)
MX (1)	MX9505187A (de)
PT (1)	PT716857E (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1289815B1 (it) *	1996-12-30	1998-10-16	Sorin Biomedica Cardio Spa	Stent per angioplastica e relativo procedimento di produzione
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
US6670355B2 (en) *	2000-06-16	2003-12-30	Wyeth	Method of treating cardiovascular disease
ES2313983T3 (es)	2000-09-19	2009-03-16	Wyeth	Esteres hidrosolubles de rapamicina.
US6399625B1 (en)	2000-09-27	2002-06-04	Wyeth	1-oxorapamycins
US6440991B1 (en)	2000-10-02	2002-08-27	Wyeth	Ethers of 7-desmethlrapamycin
US6399626B1 (en)	2000-10-02	2002-06-04	Wyeth	Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en)	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
TWI233359B (en) *	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
ZA200603888B (en) *	2001-06-01	2007-05-30	Wyeth Corp	Antineoplastic combinations
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569
DE60206512T2 (de)	2001-08-22	2006-06-22	Wyeth	Rapamycin 29-enole
MXPA04001523A (es)	2001-08-22	2004-05-31	Wyeth Corp	Dialdehidos de rapamicina.
PT1553940E (pt)	2002-07-30	2008-05-09	Wyeth Corp	Formulações parentéricas contendo um hidroxi-éster de rapamicina
BR0314397A (pt) *	2002-09-17	2005-08-09	Wyeth Corp	Formulações orais
AR042938A1 (es) *	2003-02-06	2005-07-06	Wyeth Corp	Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (de) *	2003-04-22	2007-01-24	Wyeth	Antineoplastische zusammensetzungen
PL1761540T3 (pl)	2004-05-13	2017-06-30	Icos Corporation	Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
JP2008500338A (ja) *	2004-05-25	2008-01-10	イコス・コーポレイション	造血細胞の異常増殖を治療及び／又は予防する方法
EP1804751A2 (de) *	2004-10-04	2007-07-11	QLT USA, Inc.	Okulare abgabe von polymer-abgabeformulierungen
US8313763B2 (en) *	2004-10-04	2012-11-20	Tolmar Therapeutics, Inc.	Sustained delivery formulations of rapamycin compounds
AU2006315512B2 (en)	2005-11-14	2012-11-01	Ariad Pharmaceuticals, Inc.	Administration of an mTOR inhibitor to treat patients with cancer
RU2010104916A (ru) *	2006-08-16	2011-08-20	Михаил В. Благосклонный (US)	Способ профилактики и лечения возрастных заболеваний
EP2702993B1 (de)	2006-09-13	2017-12-06	Elixir Medical Corporation	Makrocyclische lactonverbindungen und verfahren zu deren verwendung
CN102231969A (zh) *	2008-10-03	2011-11-02	万能医药公司	大环内酯化合物及其使用方法
ES2645692T3 (es)	2008-11-11	2017-12-07	The Board Of Regents,The University Of Texas System	Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
NZ631024A (en)	2008-11-13	2016-04-29	Gilead Calistoga Llc	Therapies for hematologic malignancies
US9492449B2 (en)	2008-11-13	2016-11-15	Gilead Calistoga Llc	Therapies for hematologic malignancies
SG174529A1 (en)	2009-03-24	2011-10-28	Gilead Calistoga Llc	Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
ES2685947T3 (es)	2009-04-10	2018-10-15	Haiyan Qi	Agentes antienvejecimiento
PT2421536E (pt)	2009-04-20	2015-10-20	Gilead Calistoga Llc	Métodos de tratamento para tumores sólidos
EP2456443A1 (de)	2009-07-21	2012-05-30	Gilead Calistoga LLC	Behandlung von lebererkrankungen mit pi3k-hemmern
US9364507B2 (en) *	2009-08-11	2016-06-14	Imagilin Technology, Llc	Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
AP2014007875A0 (en)	2012-03-05	2014-08-31	Gilead Calistoga Llc	Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
EP2906214A1 (de)	2012-10-12	2015-08-19	The Board of Regents of The University of Texas System	Verwendung von mtor-hemmern zur behandlung von vaskulären kognitiven störungen
EP2968281B1 (de)	2013-03-13	2020-08-05	The Board of Regents of The University of Texas System	Mtor-hemmer zur vorbeugung von darmpolypenwachstum
EP3083623A1 (de)	2013-12-20	2016-10-26	Gilead Calistoga LLC	Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
PT3083630T (pt)	2013-12-20	2019-11-15	Gilead Calistoga Llc	Procedimentos para inibidores da fosfatidilinositol 3-quinase
DK3089737T3 (da)	2013-12-31	2021-12-13	Rapamycin Holdings Llc	Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
JP6455995B2 (ja)	2014-06-13	2019-01-23	ギリアードサイエンシーズ，インコーポレイテッド	ホスファチジルイノシトール３−キナーゼ阻害剤
KR20230010641A (ko) *	2020-05-15	2023-01-19	셀진 코포레이션	ACTRIIB 리간드 트랩 및 mTOR 억제제를 사용한 빈혈 치료 방법 및 조성물
CN116459248B (zh) *	2023-04-27	2024-02-13	中国人民解放军陆军军医大学第二附属医院	雷帕霉素在制备治疗肿瘤相关性贫血的药物中的应用和药物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en) *	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US4885171A (en) *	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4401653A (en) *	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
AU658577B2 (en) *	1990-08-10	1995-04-27	Smithkline Beecham Corporation	Immunosuppressive compositions
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5321009A (en) *	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
IL101353A0 (en) *	1991-04-03	1992-11-15	American Home Prod	Pharmaceutical compositions for treating diabetes
US5091389A (en) *	1991-04-23	1992-02-25	Merck & Co., Inc.	Lipophilic macrolide useful as an immunosuppressant
DE69209183T2 (de)	1991-06-18	1996-08-08	American Home Prod	Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) *	1991-07-25	1993-04-28	Univ Louisville Res Found	Method of treating ocular inflammation
US5286731A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5288711A (en) *	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
GB9221220D0 (en) *	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
GB9302567D0 (en) *	1993-02-10	1993-03-24	Smithkline Beecham Plc	Novel compound
CH686761A5 (de) *	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.

1994
- 1994-12-13 US US08/354,977 patent/US5561138A/en not_active Expired - Lifetime
1995
- 1995-11-27 DE DE69526311T patent/DE69526311T2/de not_active Expired - Fee Related
- 1995-11-27 AT AT95308503T patent/ATE215822T1/de not_active IP Right Cessation
- 1995-11-27 EP EP95308503A patent/EP0716857B1/de not_active Expired - Lifetime
- 1995-11-27 DK DK95308503T patent/DK0716857T3/da active
- 1995-11-27 ES ES95308503T patent/ES2179862T3/es not_active Expired - Lifetime
- 1995-11-27 PT PT95308503T patent/PT716857E/pt unknown
- 1995-12-11 CA CA002164921A patent/CA2164921A1/en not_active Abandoned
- 1995-12-11 MX MX9505187A patent/MX9505187A/es unknown
- 1995-12-12 JP JP7323042A patent/JPH08208661A/ja active Pending
- 1995-12-12 KR KR1019950048544A patent/KR100423825B1/ko not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0716857A1 (de)	1996-06-19
US5561138A (en)	1996-10-01
ES2179862T3 (es)	2003-02-01
CA2164921A1 (en)	1996-06-14
HK1010345A1 (en)	1999-06-17
MX9505187A (es)	1997-04-30
DE69526311D1 (de)	2002-05-16
EP0716857B1 (de)	2002-04-10
DE69526311T2 (de)	2002-11-28
KR960021019A (ko)	1996-07-18
PT716857E (pt)	2002-08-30
DK0716857T3 (da)	2002-08-05
KR100423825B1 (ko)	2004-06-26
JPH08208661A (ja)	1996-08-13

Legal Events

Date	Code	Title	Description
2002-07-15	UEP	Publication of translation of european patent specification
2007-08-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69526311D1 (de)	2002-05-16	Verwendung von Rapamycin zur Behandlung von Anämie
DE122005000011I2 (de)	2006-02-09	Verwendung von Tomoxetin zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsst¦rungen
ATE241358T1 (de)	2003-06-15	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE362361T1 (de)	2007-06-15	Verfahren zur behandlung vaskulärer kopfschmerzen
ATE448791T1 (de)	2009-12-15	Methoden und zusammensetzungen für die behandlung von glomerulonephritis
DE69434610D1 (de)	2008-08-21	Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69528475D1 (de)	2002-11-07	Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE69715325D1 (de)	2002-10-17	Apparat zum Behandlung von Bekleidungsstücken
LV10048A (lv)	1994-05-10	Lidzeklis slimibu arstesanai un ta iegusanas process
ATE411016T1 (de)	2008-10-15	Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE205425T1 (de)	2001-09-15	Verfahren zur behandlung von festen abfällen
DE602004007942D1 (de)	2007-09-13	Chemische aktivierung und veredelung von südkieferkraftfasern
ATE345811T1 (de)	2006-12-15	Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
ATE192726T1 (de)	2000-05-15	Verfahren zur behandlung von abfallschlamm
ATE123586T1 (de)	1995-06-15	Verfahren und ofen zur behandlung von schmelzbaren abfällen.
EA199800764A1 (ru)	1999-06-24	Способ лечения или предупреждения макулярного отека или возрастной макулярной дистрофии
DE68913456D1 (de)	1994-04-07	Verfahren zur Behandlung von Stahlblech.
DE69114854D1 (de)	1996-01-04	Verfahren zur behandlung von photographischen abwässern.
NO984160D0 (no)	1998-09-10	Fremgangsmåte for behandling eller forebyggelse av interstitiell cystitt
DE69629955D1 (de)	2003-10-16	Verfahren zur behandlung von holz
DE60033569D1 (de)	2007-04-05	Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
DE69818809D1 (de)	2003-11-13	Verfahren zur behandlung von narbengewebe
DE68907569D1 (de)	1993-08-19	Mittel zur behandlung oder vorbeugung von aids.
DE69808455D1 (de)	2002-11-07	Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ATE266395T1 (de)	2004-05-15	Glycin zur vorbeugung oder behandlung von transplantatabstossungen